Benign Prostatic Hyperplasia Treatment Market Size, Share & Trends Analysis Report By Treatment Type (Pharmacological Treatment (Alpha-blockers, 5-Alpha Reductase Inhibitors, Phosphodiesterase-5 Inhibitors, Others), Minimally Invasive Procedures (Transurethral Resection of the Prostate, Laser Therapy, Prostatic Urethral Lift, Prostatic Artery Embolisation, Others), Surgical Procedures (Open Prostatectomy, Robotic-Assisted Surgery, Others)), By End-User (Hospitals, Ambulatory Surgical Centers (ASCs), Clinics, Home Care Settings), By Distribution Channel: (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies) and By Region(North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2025-2033

Benign Prostatic Hyperplasia Treatment Market Size

The global benign prostatic hyperplasia (BPH) treatment market was valued at USD 12.5 billion in 2024 and is projected to grow from USD 13.1 billion in 2025 to USD 18.5 billion by 2033, exhibiting a CAGR of 4.4% during the forecast period (2025–2033).

The global benign prostatic hyperplasia (BPH) treatment market expansion is driven by an ageing male population, advancements in minimally invasive procedures, and increasing awareness of urological health. The market is experiencing robust growth due to the rising prevalence of BPH among ageing men, technological advancements in minimally invasive procedures, and heightened awareness of prostate health. BPH, a non-cancerous prostate gland enlargement, is driving demand for effective treatments like alpha-blockers, 5-alpha reductase inhibitors, and surgical interventions such as transurethral resection of the prostate (TURP) and laser therapies.

Additionally, adopting minimally invasive techniques like prostatic artery embolisation (PAE) and UroLift offers reduced recovery times and fewer complications, stimulating market growth. Growth is further propelled by innovations in drug formulations and favourable reimbursement policies, though high treatment costs and side effects pose challenges. The market is poised for expansion as healthcare access improves in emerging regions like Asia-Pacific, supported by government initiatives and medical tourism.

BPH Treatment Market Trend

Rise of minimally invasive procedures

A prominent trend in the BPH treatment market is the increasing adoption of minimally invasive procedures, which offer reduced recovery times, lower complication rates, and enhanced patient outcomes compared to traditional surgical methods. Techniques such as transurethral resection of the prostate (TURP), laser therapies (e.g., HoLEP), and prostatic artery embolisation (PAE) are gaining traction due to their precision and efficacy. The UroLift system, a prostatic urethral lift, is particularly popular for its office-based application and minimal invasiveness.

• For instance, in April 2024, Teleflex launched the UroLift 2 System with Advanced Tissue Control, an FDA-cleared upgrade offering laser-etched markers and customisable tissue manipulation for enhanced accuracy, enhancing treatment precision for BPH patients. 

This trend is driven by patient preference for outpatient procedures and advancements in medical devices, with the Asia-Pacific region showing rapid growth due to medical tourism and improved healthcare access. The shift toward minimally invasive solutions is expected to continue, supported by innovations and increasing physician training.

Benign Prostatic Hyperplasia Treatment Market Driver

Aging male population

The global rise in the ageing male population is a primary driver of the BPH treatment market, as BPH prevalence increases significantly with age. According to the National Institute of Diabetes and Digestive and Kidney Diseases, nearly 50% of men aged 51–60 and up to 90% of those over 80 experience BPH symptoms, creating a substantial patient pool. This demographic shift and longer life expectancies amplify demand for pharmacological and surgical treatments.

• For example, in July 2024, the World Health Organisation highlighted the growing healthcare needs of older people, emphasising age-related conditions like BPH.

North America, with its advanced healthcare systems, accounted for the largest share of market revenue in 2024, while Asia-Pacific is witnessing rapid growth due to its ageing populations in countries like China and Japan. Innovations like AbbVie’s FDA-approved combination therapy in April 2024, integrating an alpha-blocker and 5-alpha reductase inhibitor, address multiple BPH symptoms, further fueling market expansion. As healthcare awareness and access improve globally, the demand for BPH treatments is expected to surge.

Market Restraining Factors

High costs of advanced treatments

A significant restraint in the BPH treatment market is the high cost of advanced treatments, which limits accessibility, particularly in low- and middle-income regions. Procedures like robotic-assisted surgeries and minimally invasive laser therapies can cost upwards of USD 20,000 per procedure, according to the Centres for Medicare & Medicaid Services. These expenses and out-of-pocket medication costs deter patients from seeking optimal care, especially in developing nations with limited healthcare reimbursement policies.

Additionally, disparities in healthcare access between urban and rural areas further exacerbated this issue, with many patients relying on less effective traditional treatments. Additionally, the side effects of medications, such as dizziness and sexual dysfunction, can lead to patient noncompliance, hindering market growth. High costs and a lack of awareness about generic alternatives restrict market expansion in budget-sensitive markets. To address this, manufacturers must invest in cost-effective solutions, and governments must enhance reimbursement frameworks.

Market Opportunity

Growth in emerging markets

Emerging markets, particularly in Asia-Pacific, present significant opportunities for the BPH treatment market due to rapid demographic changes, improving healthcare infrastructure, and rising medical tourism. The Asia-Pacific region is projected to grow, driven by large ageing populations in countries like China, India, and Japan, where BPH incidence is rising. Government initiatives, such as India’s national men’s health awareness campaign, are increasing early diagnosis and treatment adherence. Key players are capitalising on these opportunities through strategic expansions.

• For example, in October 2024, Boston Scientific opened a manufacturing site in China, enhancing its capacity to produce advanced BPH treatment devices like the Rezūm™ Water Vapour Therapy, which expanded in Europe in June 2024.

Additionally, Olympus Corporation and Astellas Pharma are investing in R&D to develop cost-effective, minimally invasive solutions tailored for emerging markets. The growing adoption of generic drugs and biosimilars further supports market growth by improving affordability. These dynamics and increasing healthcare expenditures position emerging markets as key growth areas for BPH treatment innovations.

Regional Insights

North America leads the BPH treatment market due to its mature healthcare infrastructure, widespread use of minimally invasive treatments (like UroLift, HoLEP, and laser therapies), and strong reimbursement policies. Innovations such as Teleflex’s launch of the UroLift 2 System have boosted treatment precision and outcomes. Government-backed urological research funding supports new treatment development. A growing ageing male population spurs demand for both drug and procedural care. Major medical device companies, including Boston Scientific and Medtronic, continue introducing advanced BPH solutions to ensure strong patient access. The region’s network of specialists, clinics, and awareness campaigns also helps drive early diagnosis. Overall, North America remains the market leader through innovation, accessibility, and ageing demographic trends.

U.S. Benign Prostatic Hyperplasia Treatment Market Trends

• The United States leads the global market thanks to widespread access, technological leadership, and treatment innovation. Strong research funding drives next-generation therapies, such as the National Institutes of Health’s June 2024 commitment to urology research. Major device manufacturers, including Boston Scientific and Teleflex, actively launch advanced platforms. U.S. reimbursement systems facilitate patient access to procedures. Additionally, high healthcare spending and strong R&D activity support continuous improvements in treatment options and patient outcomes, cementing the U.S. as a global market power.
• Canada’s BPH treatment market is growing modestly, supported by well-structured healthcare systems and a large ageing male population. Minimally invasive procedures like TURP and UroLift are becoming more common. Medtronic and similar companies are investing in advanced treatments tailored for Canadian needs. Public health campaigns have increased awareness, leading to earlier detection rates. As lifestyle factors contribute to rising BPH cases, demand for both surgical and drug therapies grows. Rural expansion and digital care delivery also open new access points. These combined factors drive a steady, stable growth trajectory for Canada’s market.

Asia-Pacific Benign Prostatic Hyperplasia Treatment Market Trends

Asia-Pacific’s BPH treatment market is expanding rapidly, driven by demographic shifts (large populations of ageing men), increased healthcare investment, and the rise of medical tourism. Campaigns like India's national men’s health drive early diagnosis, while China’s healthcare plan includes substantial funding for urological care. The introduction of minimally invasive options, such as Boston Scientific’s Rezūm therapy in China, and expanding facilities in Thailand and Malaysia further support growth. Generic drug availability following recent patent expirations makes treatment more affordable. Additionally, regional medical device companies and R&D centres like Olympus’s facility in Japan are tailoring solutions to local needs, lifting accessibility and physician training levels. As a result, Asia-Pacific is the fastest-growing market and is well-positioned for sustainable expansion.

• China leads Asia-Pacific’s BPH treatment industry thanks to robust government investment and rapid adoption of minimally invasive care. The healthcare expansion plan allocated major federal funding to urological services. Rising healthcare spending, alongside growing medical tourism, expands patient access. New regional guidelines promote early diagnosis and use of both drug and minimally invasive interventions. Local R&D hubs especially in Beijing and Shanghai and tech partnerships enhance treatment development and clinical trials. Falling drug prices after patent expiration also expand patient access. Overall, China is well-positioned for long-term market leadership.
• India’s BPH treatment market is the fastest-growing in Asia-Pacific, driven by an expanding rural healthcare system and increased health awareness. Urban and rural hospitals are increasingly equipped with minimally invasive devices and laser systems. Global device firms such as Boston Scientific and Astellas are tailoring cost-effective solutions for Indian markets, supported by local manufacturing and distribution. Generic drug availability post-patent expiration has reduced prescription costs. Medical tourism and domestic patient growth opportunities also fuel the market. With rising technology adoption and policy support, India is rapidly emerging as a key growth market in the global BPH treatment sector.

Europe Benign Prostatic Hyperplasia Treatment Market Trends

Europe’s market for BPH treatment is expanding steadily, underpinned by advanced healthcare systems, strong patient awareness, and favourable reimbursement. Countries like Germany, the U.K., and France are well-equipped with urology centres and early-care initiatives backed by government grants. The European Association of Urology’s outreach programs boost diagnosis rates, while minimally invasive treatments are widely used. Innovations like Boston Scientific’s Rezūm Water Vapour Therapy entering European markets are adding to the options available. Financial support for hospital training and device R&D strengthens the market, while generics coming into play post-patent expiration provide affordable medication options. Europe’s infrastructure, innovation, and policy blend make it a durable growth region.

• The U.K. market consistently grows through advanced treatment offerings and robust healthcare support. The NHS’s 2024 investment in urological training enhances procedural expertise nationwide. The National Health Service’s commitment to early diagnosis, backed by awareness campaigns, improves patient outcomes. Companies like Boston Scientific and GSK are active with device and drug portfolios. A well-developed healthcare ecosystem with strong research backing and preventive care continues to advance the UK BPH treatment landscape smoothly.
• Germany remains a key player in Europe’s BPH treatment industry due to its strong healthcare system and commitment to innovative treatments. The Federal Ministry of Health allocated substantial funding in 2024 to support urological research. Treatment adoption is high with widely available TURP and laser options (e.g., Hybrid Thulium laser, Rezūm). Strong reimbursement policies ensure patient access, while public awareness drives early intervention. Emphasis on precision medicine and strong regional integration into European treatment standards support ongoing market growth, making Germany a stable and influential market.

Treatment Type Insights

The pharmacological treatment segment holds the largest market share in 2024, accounting for approximately 45% of the global market, driven by widespread use of alpha-blockers and 5-alpha reductase inhibitors for symptom management. These medications, such as tamsulosin and finasteride, are preferred for their non-invasive nature and effectiveness in relieving lower urinary tract symptoms (LUTS). The high prevalence of BPH, with over 200 million men affected globally in 2024, per the National Institute of Diabetes and Digestive and Kidney Diseases, and the affordability of generics following patent expirations of drugs like Avodart, drive segment growth. The segment’s dominance is further supported by favourable reimbursement policies in North America and Europe, which are increasing patient access.

End-User Insights

Hospitals lead the end-user segment, capturing around 40% of the market share in 2024, due to their role as primary centres for advanced diagnostics and treatments, including minimally invasive and surgical procedures. The growth is fueled by the increasing number of BPH-related hospital visits, with the American Urological Association reporting over 1.5 million annual procedures in the U.S. alone. Hospitals offer comprehensive care, including TURP, laser therapies, and robotic surgeries, supported by advanced infrastructure and skilled urologists. Additionally, favourable insurance coverage for hospital-based procedures in North America and Europe supports segment growth. Investments in healthcare infrastructure, particularly in Asia-Pacific, further bolster this segment, ensuring hospitals remain the cornerstone of BPH treatment delivery.

Distribution Channel Insights

Hospital pharmacies dominate the distribution channel segment, holding approximately 38% of the market share in 2024, as they are the primary source of BPH medications and post-procedure prescriptions. Hospital pharmacies ensure immediate access to essential drugs like alpha-blockers and 5-alpha reductase inhibitors, which are critical for managing BPH symptoms post-diagnosis or surgery. The segment benefits from integrated healthcare systems in North America and Europe, where hospital pharmacies are linked to treatment protocols, ensuring seamless drug availability. For instance, the European Association of Urology’s 2024 guidelines emphasise standardised pharmacological protocols, boosting hospital pharmacy reliance. Growing healthcare investments in Asia-Pacific, supported by government initiatives, further enhance hospital pharmacy infrastructure, solidifying their dominance in BPH treatment distribution.

Company Market Share

The BPH treatment market is highly competitive, with key players focusing on innovation, strategic partnerships, and geographic expansion. Companies invest heavily in R&D to develop minimally invasive devices and novel drugs, targeting patient-centric care. Market leaders leverage strong distribution networks and regulatory approvals to maintain dominance, while emerging players focus on cost-effective generics and regional markets. Awareness campaigns and reimbursement policies further drive adoption.

Boston Scientific: Boston Scientific is a leading player in the market, leveraging its expertise in minimally invasive technologies. The company focuses on R&D, strategic acquisitions, and global expansion, particularly in Asia-Pacific, to strengthen its market share. Its emphasis on patient-centric solutions and partnerships with healthcare providers drives growth. Its robust distribution network and regulatory approvals ensure market leadership, with a focus on emerging markets like China and India.

Latest News:

• In October 2024, Boston Scientific opened a manufacturing site in China, enhancing its capacity to produce Rezūm therapy devices for BPH treatment. This move supports China’s growing demand for minimally invasive solutions, strengthening Boston Scientific’s position in Asia-Pacific.

Recent Developments

• September 2024- Royal Surrey NHS Foundation Trust introduced EchoLaser treatment for BPH, a minimally invasive procedure funded by the Prostate Project charity. This technology, offering rapid recovery and minimal side effects, was rolled out to address the needs of the U.K.’s ageing male population, with 50% of men over 50 affected. The initiative enhances patient quality of life and reduces hospital stays, reinforcing the U.K.’s focus on innovative BPH solutions.
• April 2024- Teleflex launched the UroLift 2 System with Advanced Tissue Control, a next-generation minimally invasive solution for BPH treatment. This system enhances precision in treating complex prostate anatomies, reducing recovery time and improving patient outcomes. The launch, supported by clinical data showing a 30% improvement in symptom relief compared to earlier models, strengthens Teleflex’s position in the U.S. and European markets, aligning with the growing demand for outpatient procedures.